 PARIS CAMBRIDGE, Mass.--BUSINESS WIRE--Regulatory News: NANOBIOTIX Euronext: NANO NASDAQ: NBTX the Company, a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment, today announced a new collaboration agreement secured by its wholly-owned subsidiary, Curadigm. Pursuant to the selection of a project involving Curadigms Nanoprimer technology as a promising option to significantl 